Nuclear localization and high levels of the Y-box binding protein YB1 appear to be important indicators of drug resistance and tumor prognosis. YB1 also interacts with the p53 tumor suppressor protein. In this paper, we explore a role for p53 in the nuclear localization of YB1. We report that various genotoxic stresses induce nuclear localization of YB1 in a small proportion of treated cells, but only in cells with wild-type p53. We go on to show directly that functional p53 is required for YB1 to translocate to the nucleus. Tumor-associated p53 mutants however are attenuated for YB1 nuclear localization as are mutants mutated in the proline-rich domain of p53. These data link the DNA-damage response of p53 to YB1 nuclear translocation. In addition, we find that YB1 inhibits p53-induced cell death and its ability to transactivate promoters of genes involved in cell death signaling. Together these data suggest that some forms of p53 cause YB1 to accumulate in the nucleus, which in turn inhibits p53 activity. These results provide a possible explanation for the correlation of nuclear YB1 with drug resistance and poor prognosis in some tumor types, and for the first time implicate p53 in the process of nuclear translocation.
Introduction
YB1, also known as DNA binding protein B (dbpB), is a member of the highly conserved Y-box family of proteins, which regulate gene transcription by binding to either double-or single-stranded TAACC elements (the Y box) contained within many eucaryotic promoters (Wolffe, 1994; Mantovani, 1998) . Y-box family members have also been shown to bind RNA in both a sequence-specific and nonspecific manner, indicating additional roles for these proteins in post-transcriptional regulation (Matsumoto and Wolffe, 1998; Sommerville, 1999) .
Several studies have demonstrated that YB1 is directly involved in the cellular response to genotoxic stress. In response to DNA-damaging agents, such as the chemotherapeutic drug cisplatin and UV irradiation, YB1 induces expression of the multidrug resistance 1 (MDR1) gene through increased binding to a Y-box element within the MDR1 promoter (Uchiumi et al., 1993; Asakuno et al., 1994; Ohga et al., 1998) . The MDR1 gene encodes an energy-dependent drug efflux pump, which is overexpressed in cancer cells resistant to many chemotherapeutic agents. Furthermore, in cultured cell lines resistant to cisplatin, overexpression of YB1 has been observed, and depletion of YB1 results in increased sensitivity to cisplatin (Ohga et al., 1996) , suggesting that YB1 plays an important role in conferring drug resistance on tumor cells.
It has been reported that YB1 is predominantly localized to the cytoplasm in both normal and tumor cells, but can translocate to the nucleus in response to environmental stresses. Such stresses include DNAdamaging agents, UV irradiation, virus infection and hypothermia (Koike et al., 1997; Okamoto et al., 2000; Stein et al., 2001; Holm et al., 2002) . Nuclear localization of YB1 protein has also been associated with poor prognosis in some types of human cancer (Bargou et al., 1997; Oda et al., 1998; Kamura et al., 1999; Shibahara et al., 2001) , whereas in other cases overexpression of YB1 is linked with unfavorable outcome (Shibao et al., 1999; Janz et al., 2002) .
Transcriptional targets of YB1 include genes associated with cell death in response to genotoxic damage including both fas (Lasham et al., 2000) , a cell deathassociated receptor, and the tumor suppressor gene, p53 (Okamoto et al., 2000) . The p53 protein is a DNA-binding transcription factor whose expression is maintained at a low level by an autoregulatory loop involving the protein MDM2 (Momand et al., 1992; Haupt et al., 1997; Kubbutat et al., 1997) , which functions as an ubiquitin ligase, targeting p53 for degradation via the ubiquitin pathway. Following genotoxic stress, this autoregulatory loop is disrupted through covalent modification of p53 including phosphorylation and acetylation (Appella and Anderson, 2001 ) some of which interfere with binding to MDM2. Disruption of the loop, together probably with deubiquitination of p53 by HAUSP (Li et al., 2002) , leads to an increase in protein level. This enables p53 to act as an efficient transcription factor to transactivate a variety of target genes, ultimately leading to cell cycle arrest or apoptosis (Hansen and Oren, 1997; Prives and Hall, 1999) . This allows DNA damage to be repaired or removal of potential tumor precursor cells from tissues.
Recent studies have shown a direct interaction between YB1 and p53 proteins with the four aromatic regions of YB1 binding between amino acids 363 and 376 in the C-terminus of p53 (Okamoto et al., 2000) . Another recent report has also indicated that YB1 and p53 interact with a common transcription factor, AP2, to coregulate the gelatinase A gene (Mertens et al., 2002) . Given that YB1 and p53 both appear to be 'activated' in response to genotoxic and other stresses, and that they interact directly, we began exploring the relation between YB1 and p53 in more detail. In this paper, we provide evidence that nuclear localization of YB1 requires wild-type (wt) p53 and, associated with this, YB1 inhibits the ability of p53 to cause cell death.
Results

Stress-induced nuclear localization of YB1 depends on p53 status
YB1 is reported to be located in the nucleus in a number of drug-resistant cell lines (Ohga et al., 1996) , and translocates to the nucleus in response to treatment with UV irradiation (Koike et al., 1997) , hypothermia (Stein et al., 2001) , the antitumor drug cisplatin (Okamoto et al., 2000) and after infection with human adenovirus type 5 (Ad5) (Holm et al., 2002) . In the latter case, nuclear translocation was reported to require expression of the p53 binding protein E1b55kD (Holm et al., 2002) .
To confirm that YB1 translocates to the nucleus after genotoxic stress and Ad5 infection, and to explore a role for p53, we determined the intracellular location of YB1 in a panel of tumor-derived cell lines that vary in their p53 status, following treatment with the DNA-damaging agents cisplatin, actinomycin D and amsacrine, and also after infection with Ad5. This was performed using indirect double immunofluorescent labeling with antibodies against YB1 and p53. We observed nuclear staining of YB1 after treatment of A549 cells with all three drugs (Figure 1 ), although the proportion showing nuclear YB1 was low. Quantitation of this after treatment of several cell lines with cisplatin showed this to be only about 5% of the total population examined (Table 1) in cells with wt p53, but nuclear YB1 was never observed in cells deficient in p53 (SaOS2 and IIICF/c).
We also examined the intracellular localization of YB1 after infection with Ad5. Results showed ( Table 1) that between 3 and 6% of infected cells contained nuclear YB1 depending on the cell type. However, again, as observed with drug treatment, no nuclear localization of YB1 was observed after infection of p53-deficient cells.
The above experiments suggest that wt p53 might be at least partially responsible for the nuclear localization of YB1.
Wt p53 is necessary for nuclear translocation of YB1
To test the possibility that wt p53 is necessary for YB1 nuclear localization, SaOS2, IIICF/c and a third p53 null cell line, SK-OV3, were transfected with wt human and mouse p53 expression constructs and the staining pattern of YB1 examined using double immunofluorescence microscopy as above. This was compared with Figure 1 YB1 nuclear localization in A549 cells after genotoxic stress. Double-labeling immunofluorescence microscopy was carried out on A549 cells treated with the anti-tumor drugs cisplatin, amsacrine and actinomycin D. p53 is stained green and YB1 is stained red. Colocalization of nuclear p53 and nuclear YB1 is shown in the merge (scale bar ¼ 50 mm) Figure 2a . YB1 was found in the nucleus of cells staining positive for p53, but was not observed in cells without p53. Moreover, YB1 and p53 appeared to be colocalized (see merge in Figure 2a ) consistent with the report that YB1 can bind p53 (Okamoto et al., 2000) . Mouse p53 (mwtp53) was also found to cause YB1 to localize in the nucleus (Figure 2b ). To be confident that YB1 nuclear localization was not just observed in the more brightly staining cells, we cotransfected SK-OV3 cells with both hwtp53 and rat YB1 (rYB1) expression constructs, or rYB1 alone. There was no detectable YB1 in the nucleus except when p53 was coexpressed. Again, YB1 and p53 were found to be colocalized. An example of these results is shown in Figure 2c . The above studies indicated that not all p53-positive cells contained nuclear YB1. We therefore determined the proportion of p53-positive cells with nuclear YB1 by direct counting. Results for all three transfected p53 null cells are shown in Figure 3 . These data represent the average proportion of p53-positive cells that show nuclear YB1 from several transfections after counting nearly 2000 cells staining positive with a p53 antibody. Depending on the cell type, between 33 and 57% of cells transfected with 2 mg of wt p53 contained nuclear YB1.
To determine if the frequency of nuclear YB1 was dependent on the amount of p53, different amounts of p53 plasmid were transfected and scored for nuclear YB1. Results for transfected SK-OV3 cells are shown in Figure 3b . These show that the proportion of cells with nuclear YB1 was 6% with 0.1 mg of p53 plasmid, which increased to about 60% with 2 mg of plasmid. Higher amounts of p53 plasmid could not be used as most cells died after transfection. Nonetheless, these data confirm the hypothesis that wt p53 is necessary for YB1 to localize to the nucleus and it probably varies with p53 concentration. To explore this apparent dependence of nuclear YB1 on p53 concentration, IIICF/c cells containing an inducible p53 construct were used. These cells (C/ERp53/7) contain a modified estrogen receptor (ER)-p53 fusion protein that is 'activated' upon addition of the estrogen analog 4-hydroxy tamoxifen (4-OHT; Littlewood et al., 1995; Vater et al., 1996) . C/ERp53/7 cells were treated with differing amounts of 4-OHT ranging from 0.2 to 2 mm, and subsequently immunocytochemistry was carried out. To confirm that these cells induced a functional p53, we tested for expression of the cyclin-dependent kinase inhibitor p21 WAF1/CIP1 , before and after treatment with 4-OHT. The gene encoding p21
waf1/CIP1 is a major target of the p53 tumor suppressor (El-Deiry et al., 1993) . Results ( Figure 4a ) show strong staining for p21 WAF1/CIP1 after treatment with 0.2 and 2 mm 4-OHT, which is not detected in the absence of 4-OHT. This result confirms that these cells contain a functionally inducible p53. In Figure 4b , results show that the proportion of cells having nuclear YB1 increased from about 5% without 4-OHT to almost 100% after treatment with 2 mm 4-OHT. This was not because of effects of 4-OHT alone as cells expressing ER only did not show nuclear YB1 (data not shown) and IIICF/c cells transfected with p53 and also treated with 2 mm 4-OHT showed no more YB1 nuclear-positive cells than those without 4-OHT ( Figure 4c ). These experiments show clearly that nuclear localization of YB1 requires p53.
Tumor-associated p53 mutants are defective for YB1 nuclear localization
To confirm that functional p53 is required for YB1 nuclear localization, two tumor-associated mutants, C242S and R273H, were also examined after transfection of all three p53 null cell lines. Both mutants are impaired for transcriptional transactivation ability (Bissonnette et al., 1997; Bullock et al., 1997) and probably for other functions as well (Ory et al., 1994) . An example of the immunofluorescent staining after transfection of SK-OV3 cells is shown in Figure 2d , and quantitation of nuclear YB1 from the staining is shown with these p53 mutants in Figure 3 . Nuclear YB1 was evident in some cells staining positive for mutant p53 but at a considerably lower proportion than for hwtp53. For R273H, this ranged from 4% in IIICF/c (33% for hwtp53) to 19% in SK-OV3 (57% for hwtp53) and for C242S, from less than 1% in SaOS2 (36% for hwtp53) to 12% in SK-OV3 (57% for hwtp53). These data, together with those in Figure 4 , strongly suggest that nuclear translocation of YB1 requires a functionally active p53. The p53/YB1 complex is not required for nuclear translocation of YB1
As YB1 is able to bind p53, it seemed possible that YB1 migrates to the nucleus along with p53, although the data with the tumor-associated mutants would argue against this explanation, as the C terminus containing the reported YB1 binding site (amino acids 363-376, Okamoto et al., 2000) is intact in these mutants. Nonetheless, to test this possibility formally, SK-OV3 cells were transfected with mwtp53, hwtp53 and mutants deleted for the C-terminal end (DCT28 for mouse and DCT30 for human). Results ( Figure 5 ) show that both wt p53 and C-terminal mutants caused YB1 nuclear localization in a similar proportion of cells (about 50%). These data suggest that YB1 and p53 do not have to physically interact for YB1 to localize to the nucleus. It could be that there is another YB1 binding site on p53, but immunoprecipitation/Western blotting experiments suggest that this is not the case (data not shown).
Proline domain mutants of p53 are attenuated for YB1 nuclear localization
To explore the mechanism of nuclear translocation of YB1, several mouse p53 deletion mutants were tested after transfection of SK-OV3 cells. The quantitative results from immunocytochemistry experiments for some of these mutants are shown in Figure 6 . Mutant D14-66 was highly attenuated for YB1 nuclear translocation with only 8% of p53-positive cells showing nuclear YB1 compared with around 50% for mwtp53. By contrast, mutant D14-43 showed nuclear YB1 in 49% of p53-positive cells, similar to mwtp53. The deletion in mutant D14-66 extends into the proline-rich domain of p53 that has been implicated in regulating the ability of p53 to induce apoptosis (Walker and Levine 1996; Zhu et al., 1999) in response to DNA damage (Baptiste et al., 2002) . We therefore tested other proline domain mutants. All of these mutants were attenuated for YB1 nuclear localization ( Figure 6 ). Thus, the proline domain of p53 appears to play a role in regulating nuclear localization of YB1.
YB1 inhibits p53-dependent cell death
As YB1 nuclear localization occurs in some cells after treatment with DNA-damaging agents and this appears to be linked to a p53 domain required for DNA damageinduced apoptosis, we asked whether YB1 might influence the ability of p53 to induce cell death/ apoptosis. SaOS2 and IIICF/c cells were transfected with hwtp53 and cotransfected with a plasmid expressing the green fluorescent protein (GFP), along with a plasmid expressing rat YB1 (rYB1). Cells that die are represented by loss of the GFP-positive population. All data are expressed relative to the vector (CMVNeo) control. Results show that transfection of cells with hwtp53 resulted in a substantial reduction in live cells (Figure 7 ). When 0.25 mg of rYB1 was transfected alone, it had no effect on the viability of either cell type (Figure 7) . However, when rYB1 was transfected along with hwtp53, it reduced the ability of p53 to cause cell death, such that the proportion of viable cells was now increased to between 50 and 80% of the vector control in both cell types. Of interest, small amounts of YB1 had a powerful inhibitory effect on cell death induced by p53, and increasing the amount of YB1 plasmid in the transfection mixture did not lead to greater inhibition.
YB1 inhibits the ability of p53 to transactivate genes that regulate apoptosis
In general, p53 functions as a transcription factor to transactivate genes to induce cell cycle arrest or apoptosis (see Introduction). As YB1 inhibits p53-induced cell death, we therefore asked whether YB1 affects the ability of p53 to regulate expression of genes involved in apoptosis. To do this, a reporter assay was carried out using the promoter from the APAF-1 and Noxa genes linked to the luciferase reporter gene. Firstly, to show that both gene promoters are transactivated by p53 (Oda et al., 2000b; Fortin et al., 2001; Moroni et al., 2001; Robles et al., 2001) , the reporter constructs were transfected into cells along with hwtp53 or the defective tumor-associated mutants R273H and C242S. Results (Figure 8a) show that hwtp53 activated the APAF-1 promoter about 2.5-fold above the CMVNeo control and the Noxa promoter about sevenfold. Neither p53 mutant nor hYB1 activated either promoter.
To determine the effect of YB1 on p53-dependent transactivation of these promoters, a similar experiment was carried out, but differing amounts of YB1 were included in the transfection mixture. In this case human (h), B1 was used. The results are shown in Figure 8b as a percentage of the p53 activation levels. Cotransfection with 0.06 mg of a hYB1 expression plasmid reduced p53 transactivation of both promoters about 50%, which was further reduced to less than 10% with 0.25 mg of hYB1. We also examined whether YB1 inhibited the ability of p53 to transactivate the promoter of the p21 WAF1/CIP1 gene. A 30-50% inhibition was observed, but not until 1 mg or more of YB1 was added (data not shown). These experiments suggest that YB1 can inhibit the ability of p53 to transactivate its target genes, particularly those associated with cell death.
YB1 nuclear localization is associated with inhibition of p53 activity
Experiments shown above indicate that a functional p53 is required for nuclear localization of YB1. Other experiments have also shown that YB1 inhibits p53 functions. However, a link between these two phenomena has not been established. To address this issue, we took advantage of one of the proline domain mutants, D61-88, which, although attenuated for YB1 nuclear localization, is not, as far as we have investigated, attenuated for other p53 functions. A result showing that D61-88 is at least as capable as wtp53 at 
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You Fang Zhang et al transactivating the Noxa promoter is shown in Figure 9a . In other studies, we have also shown that D61-88 activates three other p53-dependent promoters as well as wt p53 and kills cells as efficiently as wtp53 (S Edwards, L Hananeia, M Eccles, Y-F Zhang and A Braithwaite, submitted for publication). We therefore used this mutant to determine whether nuclear localization of YB1 is required for its ability to inhibit p53-dependent transactivation. Cells were transfected with either mwtp53 or D61-88 along with differing amounts of hYB1, and the ability of p53 to transactivate the Noxa promoter was determined. Results ( Figure 9b) show that hYB1 inhibits the ability of both mwtp53 and D61-88 to transactivate the promoter, but it inhibits mwtp53 much more effectively. For example, at 0.01 mg of hYB1, mwtp53 is inhibited by about 80%, whereas at the same hYB1 concentration, D61-88 is only inhibited by 20%. Although high amounts of hYB1 cause a substantial inhibition of D61-88 activity, mwtp53 activity is always inhibited 3-4-fold more. This Nuclear localization of Y-box factor YB1 requires wild-type p53 You Fang Zhang et al difference in inhibitory ability is similar to the difference in the proportion of cells showing nuclear YB1 (about threefold, Figure 6 ). These results suggest that nuclear localization may be required for YB1 to inhibit p53 activity.
Discussion
As a transcription factor, the Y-box factor YB1 has been shown to regulate diverse genes involved in growth control and DNA replication (Wolffe, 1994; Ladomery and Sommerville, 1995) . YB1 has also been implicated in the cellular response to DNA damage by activating a major drug resistance protein, MDR1 . Associated with this DNA damage-induced gene activation is a translocation of YB1 to the nucleus from the cytoplasm where it normally resides. In this paper, we carried out DNA-damage experiments and explored a role for p53 in nuclear translocation of YB1. We confirm that YB1 translocates to the nucleus after treatment of cells with DNA-damaging agents, using the antitumor drugs cisplatin, actinomycin D and amsacrine and also after adenovirus infection (Figure 1 ). However, we also find that the frequency of cells with nuclear YB1 Figure 9 YB1 is less able to repress transactivation of a p53 proline domain mutant. IIICF/c cells were transfected with the Noxa reporter construct along with mwtp53, D61-88 and varying amounts of hYB1. Cells were harvested after 48 h and assayed for luciferase activity. (a) Mutant D61-88 transactivates the Noxa promoter as well as mwtp53. Luciferase activity is measured relative to the mock value (set at 1.0). (b) The ability of YB1 to repress p53 transactivation is measured as the percentage of the p53 transactivation level of each of mwtp53 and D61-88 as in Figure 8 Nuclear localization of Y-box factor YB1 requires wild-type p53 You Fang Zhang et al is less than 10% of the total population in all cases (Table 1) . Most published studies showing nuclear YB1 have used Western blotting on subcellular fractions (Bargou et al., 1997; Okamoto et al., 2000) . These studies also show that most YB1 is still cytoplasmic. One study however used immunocytochemistry (Koike et al., 1997) after treatment of cells with UV. Although not quantitated, the majority of cells showed a perinuclear distribution of YB1, with few showing a clear nuclear location. Our observations indicating nuclear translocation of YB1 to be a rare event after genotoxic stress is therefore probably consistent with other published data. A possible reason for the low frequency of DNA damage-induced nuclear translocation of YB1 is discussed later. Despite the low frequency, nuclear YB1 is only observed in cells that contain a wt p53 gene. This finding led us to consider the possibility that nuclear translocation of YB1 is p53 dependent.
To test this possibility, we transfected three p53 null cell lines with wt human and mouse p53 constructs. Results (Figures 2, 3 and 5) of several detailed immunocytochemistry experiments show that only in cells expressing p53 is nuclear YB1 detected. However, this is never 100%, as at best, about 50% of p53 transfected cells show nuclear YB1. This is in part due to cell death as the amount of p53 plasmid is increased. To avoid this problem, a p53-inducible cell line was used. We find that as more functional p53 is induced, the proportion of cells with nuclear YB1 increases to almost 100% (Figure 4 ). These data confirm the hypothesis that functional p53 causes YB1 to localize to the nucleus.
To determine whether YB1 translocates to the nucleus by complexing with p53 (Okamoto et al., 2000) , p53 mutants deleted for the YB1 binding site were used (DCT28 and DCT30). These mutants show a similar percentage of nuclear YB1 as wt p53 ( Figure 5 ). This finding implies that YB1 translocation is not a passive event in which it 'piggy-backs' on p53, but rather requires some functional activity of p53. This conclusion is further supported by experiments with the two tumor-derived mutants of p53 (C242S and R273H). Both mutants are localized to the nucleus, but despite being theoretically able to bind YB1 (the C-terminus is intact), they are significantly attenuated in their ability to cause nuclear translocation of YB1 (Figures 2d and  3) . Nonetheless, these data also support the hypothesis that functional p53 is required for causing YB1 nuclear translocation.
A number of other p53 mutants were tested for their ability to translocate YB1 to the nucleus. We find that those mutants deleted for portions of the proline-rich region, implicated in regulating the apoptotic response of p53 to DNA-damaging drugs (Walker and Levine, 1996; Zhu et al., 1999; Baptiste et al., 2002) , are all attenuated for nuclear YB1 translocation. Such data link the DNA-damage response of p53 to nuclear localization of YB1. As a result of this, we tested whether YB1 might inhibit the ability of p53 to induce cell death. Results (Figure 7) show that small amounts of cotransfected YB1 are able to reverse the ability of p53 to cause death. Over a similar dose range, YB1 is also able to inhibit the ability of p53 to transactivate the promoters of two genes (APAF-1 and Noxa) involved in regulating p53-dependent cell death. This inhibition of p53 transactivation is less efficient with a mutant p53 that is attenuated for nuclear translocation of YB1 (Figure 9b ). This result suggests that inhibition of p53 transactivation may require YB1 to be in the nucleus, although other p53 mutants will need to be examined to confirm this suggestion. Over the same concentration range, YB1 does not appreciably affect the ability of p53 to transactivate the p21 WAF1/CIP1 promoter, involved in mediating a p53-dependent cell cycle arrest (data not shown). These data suggest that YB1 can inhibit the ability of p53 to cause cell death in a relatively selective manner. A recent report has shown that treatment of cells with an antisense YB1 causes a modest (about 30%) inhibition of p21 WAF1/CIP1 promoter activity suggesting that YB1 actually upregulates p53 expression (Okamoto et al., 2000) . This stands in direct contrast to our results with the APAF-1 and Noxa promoters. However, we have carried out our experiment many times, and with other p53-dependent promoters, and we have never found any evidence that YB1 positively regulates p53 activity.
Much of the data in this paper imply that functional p53 is necessary for YB1 nuclear localization. As a direct complex between YB1 and p53 appears not to be involved (Figure 5 ), it seems likely that p53 causes nuclear translocation of YB1 by activating a downstream target gene, the product of which mediates this translocation process. However, the fact that mutant D61-88 is attenuated for YB1 nuclear localization but is still able to function efficiently as a transcription factor seems paradoxical. It could be that p53 provides a function unrelated to its transcriptional ability although no other activity has been described. The most likely explanation therefore is that the D61-88 is defective in activating an unidentified downstream p53 target gene required for nuclear translocation of YB1. Presumably, the product of this gene also regulates the response of p53 to DNA damage, as this appears to be the main role of the proline domain (Baptiste et al., 2002) .
The mechanism of transcriptional repression by YB1 is also not clear. It could be that nuclear YB1 complexes with p53 to prevent it from binding to its response element or to another transcription factor (Mertens et al., 2002) , or that it binds p53 on promoters and prevents it from interacting with other transcription factors required to stimulate transcription. YB1 was shown not to cause a p53 supershift in EMSAs (Okamoto et al., 2000) , which suggests that interaction with p53 off promoters is more likely. However, this issue needs much more investigation.
The data in this paper generally support the case that p53 is required for YB1 to localize in the nucleus, and that YB1 can in turn inhibit p53 activity, particularly its ability to cause cell death. Despite this, it is not clear why after drug treatment of p53-positive cells so few exhibit nuclear YB1, compared to those transfected with p53 expression plasmids. This is not because of the cell cycle stage differences, as drug-treated cells were largely in G 1 or G 2 (data not shown) and the adenovirusinfected cells were largely in S phase , yet a similar proportion of cells with nuclear YB1 was observed. The low proportion of drug-treated cells with nuclear YB1 is also not because of widely different p53 concentrations as, for example, Western blotting has shown that actinomycin D increased p53 protein to levels similar to those achieved by transfection (data not shown). The many immunocytochemistry experiments also have not indicated marked differences in the levels of p53 expressed upon drug treatment compared with transfection. Nonetheless, there are qualitative differences. In general, DNA damage stabilizes p53 as a consequence of a variety of covalent modifications, principally phosphorylation and acetylation (Prives and Hall, 1999; Appella and Anderson, 2001) , which frequently disrupt the MDM2 autoregulatory loop. Although it is sometimes argued that different DNAdamaging signals (e.g. UV compared with cisplatin) cause different modifications to p53, there is little clear evidence to support such specificity. There is indeed considerable heterogeneity of p53 modifications in response to a given stress signal (Prives and Hall, 1999; Appella and Anderson, 2001) suggesting that there are different functional forms of p53. These different functional forms probably carry out different activities as has occasionally been shown (Oda et al., 2000a) . This is much less likely to be the case for p53 proteins expressed from a transfected template, which are not (or weakly) stabilized by stress. Given this, it seems likely that only a subpopulation of cells expressing stressactivated p53 proteins will have sufficient p53 in the correct form to stimulate YB1 to relocate to the nucleus. Such a scenario in fact would be desirable, otherwise whenever a p53 response is initiated, it would be rapidly inhibited by nuclear YB1.
YB1 is known to induce expression of the multidrug resistance 1 (MDR1) gene (Uchiumi et al., 1993; Asakuno et al., 1994; Ohga et al., 1998) and is highly expressed in cultured cell lines resistant to cisplatin (Ohga et al., 1996) . Moreover, depletion of YB1 results in increased sensitivity to cisplatin (Ohga et al., 1996) . These data suggest that YB1 plays an important role in conferring drug resistance on tumor cells. In addition, nuclear localization of YB1 has also been linked to drug resistance (Bargou et al., 1997) and has been shown to be of prognostic significance in several tumors, including ovarian tumors (Kamura et al., 1999) , osteosarcomas (Oda et al., 1998) and breast tumors (Bargou et al., 1997) . Although the defects in the p53 gene are common in about 50% of all tumors (Hollstein et al., 1991) , functional inactivation of p53 is likely to be occurring in the remainder. From our observations, it is tempting to speculate that in rare cases, some activated forms of wt p53 protein cause YB1 to accumulate in the nucleus. This would in turn increase drug resistance, by activation of MDR1, and at the same time make cells more resistant to apoptosis, by inhibiting p53 activity. Such a mechanism would aid in the development of drug-resistant cell clones, thereby promoting the survival of some tumor cells.
Materials and methods
Cell lines
Three p53 null cell lines were used in our experiments -SK-OV3, SaOS2 (ATCC# HTB-85) and IIICF/c (Rogan et al., 1995) . Three genetically wt p53 cell lines were also used -A549 (ATTCC# CCL-185), RKO and HeLa (ATCC#CCL-2). All cells were maintained in DMEM containing 10% FCS and 8 mm l-glutamine in a humidified atmosphere containing 10% CO 2 , at 371C. A p53-inducible cell line (C/ERp53/7) derived from IIICF/c cells was also used as described in the text. The p53 protein is activated by treatment of cells with 4-OHT as described previously (Littlewood et al., 1995; Vater et al., 1996) . These cells were maintained in DMEM with 10% FCS but without phenol red, which acts as an estrogen receptor agonist. Full details of the construction and properties of these cells will be described elsewhere.
Drug treatments
Subconfluent (2-3 Â 10 5 ) cells were treated with cisplatin (Sigma) at 1 mg/ml, amsacrine (gift from B Baguley) at 1 mg/ ml and actinomycin D (Sigma) at 0.1 mg/ml for 24 h. Cells were then fixed and stained for immunofluorescent labeling as described below.
Adenovirus infection
Depending on the cell type, subconfluent (2-3 Â 10 5 ) cells were infected with human adenovirus at 10-50 cytopathic effect units (CPEU) of virus per cell depending on the cell type for 24 h. Cells were then fixed and stained for immunofluorescent labeling as described below.
Plasmids
Control vector CMVNeo (Braithwaite et al., 1987) ; CMV human wt p53; tumor-associated mutants CMVC242S and CMVR273H (Jackson et al., 1994) ; CMVNc9 expressing wt mouse p53 (Ginsberg et al., 1991) ; p53 mutants DCT28 and DCT30, lacking the C-terminal 28 and 30 amino acids, respectively, of mouse and human p53; proline domain mutants of mouse p53 (constructions to be reported elsewhere) and PCDNA3YB1-expressing rat or human YB1 (Lasham et al., 2000) were used as the expression plasmids in this paper. In addition, Noxa-luciferase and APAF-1-luciferase were used as reporter plasmids in the transcription assays.
Cell transfection
Subconfluent monolayers of cells were transfected with plasmid DNA made up of CMVNeo or test plasmid in different amounts depending on the experiment. FuGENE 6 reagent (Roche Molecular Biochemicals) was used as the transfecting mediator according to the manufacturer's instructions. In most cases, cells were transfected for 48 h, unless otherwise indicated, and analyses were carried out. Around 25% transfection efficiency was often achieved.
Indirect immunofluorescence microscopy
Cells (2-3 Â 10 4 ) were grown on coverslips, transfected with a total of 2 mg of plasmid, then incubated for 48 h (or otherwise indicated) in a 24-well plate. Cells were fixed with methanol at À201C. The fixed cells were permeabilized with PBS containing 0.2% Triton X-100 for 15 min and then preincubated with PBS containing 2% normal goat serum, 5% bovine serum albumin (BSA) and 0.2% Triton X-100. Mouse monoclonal antibody against human p53 (DO-1; Santa Cruz) was used at a 1 : 500 dilution; mouse monoclonal antibody against human p21 WAF1/ CIP1 (F-5; Santa Cruz) was used at a 1 : 200 dilution; in order to detect all mutant mouse p53 proteins, a monoclonal antibody cocktail containing pAb 242, pAb 248 (Yewdell et al., 1986) and pAb 200-47 (Dippold et al., 1981) was used as neat supernatants; and a polyclonal antiserum against YB1 (Ohga et al., 1996) was used at a 1 : 2000 dilution. The specificity of antibody to YB1 was verified by immunoblotting, which confirmed published data (Ohga et al., 1996) . For immunofluorescence analysis, cells were incubated in a mix of secondary antibodies, anti-mouse IgG (Alexa 488, Molecular Probe) and anti-rabbit IgG (Alexa 594, Molecular Probe) at a 1 : 400 dilution for 1 h. Coverslips were mounted with 80% glycerol in PBS. Immunostaining of the two proteins was evaluated and photographed with a fluorescence microscope equipped with a digital camera.
Cell counting
All coverslips were scanned at Â 40 magnification. The total cell number, the number of cells expressing p53 and the number of cells having YB1 located in the nucleus were systematically sampled field by field. The p53 transfection efficiency and the ratio of YB1 nuclear localization to p53 expression in the cell population were obtained and presented as histograms.
Flow cytometry
Cells (2-3 Â 10 5 ) were transfected with the indicated expression constructs and with 0.2 mg of a plasmid expressing the GFP expression. The total amount of transfected DNA was 2.2 mg per dish. At 48 h post-transfection, cells were harvested, centrifuged and incubated with PBS containing 3 mg/ml propidium iodide (PI) for 30 min. Cells were then pelleted and resuspended in sample buffer containing 2% BSA. The cell population was analysed using FACS gating for GFP-positive (FL1) and PI (FL2)-negative (viable) cells.
Reporter assays
Cells (2-3 Â 10 5 ) were transfected with luciferase reporter constructs as described above. The total amount of transfected plasmid was 4 mg. At 48 h after transfection, or as indicated, cells were counted, lysed and assayed for luciferase activity using the Luciferase assay kit (Promega) according to the manufacturer's instructions.
